How to Read a Cannabis or CBD Product Label: What Regulators and Analyses Show

By Cannible Editorial

2026-08-08

The most important distinction is between what a label claims, what a laboratory analysis found, and what a regulator has approved. For an adult consumer, read the stated cannabinoid and amount as product information to verify—not as proof of FDA approval, medical effectiveness, or exact contents. FDA says it has not approved a marketing application for cannabis to treat any disease or condition, although it has approved one cannabis-derived and three cannabis-related prescription drug products. 1

This article is general information, not individualized medical, legal, dosing, or product-selection advice. For a personal decision, consult a clinician, pharmacist, or other qualified professional.

Start by identifying the regulatory category

Do not treat these categories as interchangeable. A dietary supplement, an FDA-approved drug, a state-authorized or state-regulated cannabis product, a certificate of analysis, and a marketing claim can describe different aspects of a product. FDA states that products containing cannabis or cannabis-derived compounds remain subject to the agency’s requirements under the Federal Food, Drug, and Cosmetic Act, including when the material is classified as hemp under the 2018 Farm Bill. 1

The federal hemp definition covers Cannabis sativa and its derivatives, extracts, cannabinoids, and related materials with no more than 0.3 percent delta-9 THC on a dry-weight basis; the supplied regulatory material says that qualifying hemp was removed from the federal Controlled Substances Act. That federal definition does not, by itself, establish that a finished CBD or cannabis product is an FDA-approved drug, a dietary supplement, or lawful in every setting. 1

FDA-approved drugs are a specific regulatory category: FDA says the approved cannabis-derived and cannabis-related drug products are available only with a prescription from a licensed healthcare provider. A product being sold in a store or online, or carrying a medical-sounding statement, is not evidence supplied here that it belongs to that category. 1

The supplied FDA material separately addresses states that allow cannabis to be sold for medical uses without FDA approval. Therefore, state availability or a state-market label should not be read as proof of FDA approval. The evidence supplied here does not describe particular state labeling rules, licensing systems, or testing requirements, so those details should not be inferred from the packaging. 1

Read the cannabinoid and amount claims carefully

First identify which compound the label names—such as CBD, delta-8 THC, delta-9 THC, or another cannabinoid—and whether the amount is presented per gummy, per serving, or for the whole package. The analytical studies supplied here measured cannabinoid concentrations in specific product samples; they do not establish that every product with the same format or label has the same contents. 2 3 4

Laboratory evidence from a study of 56 selected CBD gummy products found a mean of 21.38 milligrams of CBD per gummy, with a range of 5.70 to 59.99 milligrams. In that sample, 70 percent of gummies differed by more than 10 percent from the CBD dose listed on the packaging. This is a finding about the tested gummies, not a measurement of all CBD gummies. 3

The same gummy study found delta-9 THC in 39 percent of the tested products, with concentrations ranging from 0.019 to 0.88 milligrams per gummy; nine products, or 16 percent of those tested, contained more than 0.4 milligrams per gummy. Within-product testing of 10 products also found substantial variation from gummy to gummy. These laboratory findings show why a CBD-only claim does not necessarily tell a consumer whether THC was detected in the tested sample. 3

A separate laboratory study analyzed 19 commercial delta-8 THC products. Delta-8 THC was detected in 95 percent of the sample products, and the relationship between advertised and measured delta-8 THC content was weak. Delta-9 THC was detected in 35 percent of the products and CBD in one product. The study reported a wide range of measured delta-8 THC content and concluded that most analyzed products contained amounts that could cause intoxication. 2

Treat “lab-tested” and a certificate of analysis as evidence to examine

“Lab-tested” is a marketing or packaging claim, not the laboratory result itself. In the delta-8 study, the researchers compared advertised content with independent laboratory analysis; the study also reported that the absence of a “lab-tested” label was associated with a smaller difference between labeled and measured amounts. That association does not show that the phrase proves accuracy, safety, or regulatory approval. 2

A certificate of analysis is distinct from a label claim, but the evidence supplied here does not establish a universal definition, required format, laboratory-accreditation rule, reporting threshold, or way to authenticate a certificate. The supplied analyses instead show what researchers measured in selected products: cannabinoid concentrations, possible variation within a bottle, and in some cases other cannabinoids. Do not treat the mere existence of a certificate claim as equivalent to FDA approval. 2 3 4 1

When examining an analytical document, the relevant questions are whether it identifies the tested product, states which cannabinoids were measured, and reports the measured amount. Those are features reflected in the supplied studies’ analytical aims and methods, but the evidence does not show that every commercial certificate contains them or that a certificate predicts the contents of every package. 2 3 4

Know what the label evidence can and cannot establish

Laboratory analysis answers a composition question: what was detected or quantified in the tested sample. It does not establish that a product treats a disease, is appropriate for a particular person, or has been evaluated as an FDA-approved drug. The supplied regulatory evidence says FDA has not approved cannabis itself for treatment of any disease or condition, while the approved cannabis-derived and cannabis-related drugs are a separate prescription category. 1 2 3 4

The CBD gummy analysis found that concentrations could vary among individual gummies in the same bottle, including CBD coefficients of variation from 2.1 to 27.1 percent in the 10 products assessed for within-product consistency. This does not determine the contents of an untested bottle, and it does not provide individualized dosing guidance. 3

An HPTLC laboratory study tested five commercial oils and three e-liquids available in Costa Rica. Its validated method quantified CBD and screened for other phytocannabinoids; some tested samples showed CBD overlabeling or underlabeling and tentative delta-9 THC. Because this sample was limited to eight products in Costa Rica, its findings should not be generalized to all oils, e-liquids, countries, or product lines. 4

A practical label-reading checklist

Identify the claimed cannabinoid and the claimed amount per unit or serving, and distinguish that claim from an independently measured result. 2 3

Look for whether the product makes a medical claim, but do not treat that claim as evidence of FDA approval. FDA’s approved cannabis-derived and cannabis-related products are a separate prescription-drug category. 1

If a product says “lab-tested,” look for the underlying analytical information rather than relying on the phrase alone. The supplied delta-8 analysis found only a weak relationship between advertised and measured content in its sample. 2

Check whether THC or other cannabinoids are reported, because the tested CBD gummies and delta-8 products sometimes contained cannabinoids beyond the headline claim. 2 3 4

Keep the scope of any test in view: the reported results apply to the products and samples analyzed, not automatically to every product carrying a similar label. 2 3 4